← Leaderboards
Tal Teitz
Creighton University
$2,542,267
Attributed
$2,542,267
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $658.4K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,542,267 · 2
By mechanism
R01$2,286,732 · 1
P20$255,535 · 1
Top collaborators
No co-investigators on record.
Most similar at Creighton University
Same institution · by research overlap
- Jonathan Paul Fleegel$128,617
- Matthew A Ingersoll$121,047
Others in their field
Other Emerging Leaders on “Ebselen”
- Jonathan Kil · Sound Pharmaceuticals, Inc.$4,174,965
- Jaichandar Subramanian · University Of Kansas Lawrence$1,615,075
- Blase Christopher Billack · St. John'S University$915,339
- Deanna Marie Tiek · Northwestern University$506,454
- Sergei Svarovsky · Sapphire Biotech, Inc.$395,880
- Marisa L. Zallocchi · Ting Therapeutics, Inc.$220,653
Research focus
EbselenHair CellsDexamethasoneDrug RepurposingCisplatinFda ApprovedCochleaAnti-Inflammatory AgentsClinical TrialsDoseAffectBraf GeneAuditoryExperimental StudyCell DeathBenchmarkingCell LineCell PhysiologyBiologicalCisplatin Induced Hearing LossCessation Of LifeAgingAntioxidantsHearing Impairment
Grant awards (7)
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss$533,267
R01 · FY2025 · DC · contact PI
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss$533,267
R01 · FY2024 · DC · contact PI
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss$1
R01 · FY2024 · DC · contact PI
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss$402,857
R01 · FY2023 · DC · contact PI
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss$414,483
R01 · FY2022 · DC · contact PI
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss$402,857
R01 · FY2021 · DC · contact PI
Repurposing an FDA Approved Drug, B-Raf Inhibitor Dabrafenib, for Protection from Cisplatin- and Noise-Induced Hearing Loss$255,535
P20 · FY2021 · GM · contact PI